Interferon Lambda: A New Sword in Cancer Immunotherapy
The discovery of the interferon-lambda (IFN-λ) family has considerably contributed to our understanding of the role of interferon not only in viral infections but also in cancer. IFN-λ proteins belong to the new type III IFN group. Type III IFN is structurally similar to type II IFN (IFN-γ) but func...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2011-01-01
|
| Series: | Clinical and Developmental Immunology |
| Online Access: | http://dx.doi.org/10.1155/2011/349575 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832563709685268480 |
|---|---|
| author | Ahmed Lasfar Walid Abushahba Murugabaskar Balan Karine A. Cohen-Solal |
| author_facet | Ahmed Lasfar Walid Abushahba Murugabaskar Balan Karine A. Cohen-Solal |
| author_sort | Ahmed Lasfar |
| collection | DOAJ |
| description | The discovery of the interferon-lambda (IFN-λ) family has considerably contributed to our understanding of the role of interferon not only in viral infections but also in cancer. IFN-λ proteins belong to the new type III IFN group. Type III IFN is structurally similar to type II IFN (IFN-γ) but functionally identical to type I IFN (IFN-α/β). However, in contrast to type I or type II IFNs, the response to type III IFN is highly cell-type specific. Only epithelial-like cells and to a lesser extent some immune cells respond to IFN-λ. This particular pattern of response is controlled by the differential expression of the IFN-λ receptor, which, in contrast to IFN-α, should result in limited side effects in patients. Recently, we and other groups have shown in several animal models a potent antitumor role of IFN-λ that will open a new challenging era for the current IFN therapy. |
| format | Article |
| id | doaj-art-5e0d9edb7f2542afa926269c4e796e8a |
| institution | Kabale University |
| issn | 1740-2522 1740-2530 |
| language | English |
| publishDate | 2011-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Clinical and Developmental Immunology |
| spelling | doaj-art-5e0d9edb7f2542afa926269c4e796e8a2025-02-03T01:12:48ZengWileyClinical and Developmental Immunology1740-25221740-25302011-01-01201110.1155/2011/349575349575Interferon Lambda: A New Sword in Cancer ImmunotherapyAhmed Lasfar0Walid Abushahba1Murugabaskar Balan2Karine A. Cohen-Solal3Department of Biochemistry and Molecular Biology, University of Medicine and Dentistry of New Jersey-New Jersey Medical School, University Hospital Cancer Center, 205 South Orange Avenue, Newark, NJ 07103, USADepartment of Medicine, Division of Medical Oncology, UMDNJ-Robert Wood Johnson Medical School, The Cancer Institute of New Jersey, 195 Little Albany Street, New Brunswick, NJ 08903, USADepartment of Medicine, Division of Medical Oncology, UMDNJ-Robert Wood Johnson Medical School, The Cancer Institute of New Jersey, 195 Little Albany Street, New Brunswick, NJ 08903, USADepartment of Medicine, Division of Medical Oncology, UMDNJ-Robert Wood Johnson Medical School, The Cancer Institute of New Jersey, 195 Little Albany Street, New Brunswick, NJ 08903, USAThe discovery of the interferon-lambda (IFN-λ) family has considerably contributed to our understanding of the role of interferon not only in viral infections but also in cancer. IFN-λ proteins belong to the new type III IFN group. Type III IFN is structurally similar to type II IFN (IFN-γ) but functionally identical to type I IFN (IFN-α/β). However, in contrast to type I or type II IFNs, the response to type III IFN is highly cell-type specific. Only epithelial-like cells and to a lesser extent some immune cells respond to IFN-λ. This particular pattern of response is controlled by the differential expression of the IFN-λ receptor, which, in contrast to IFN-α, should result in limited side effects in patients. Recently, we and other groups have shown in several animal models a potent antitumor role of IFN-λ that will open a new challenging era for the current IFN therapy.http://dx.doi.org/10.1155/2011/349575 |
| spellingShingle | Ahmed Lasfar Walid Abushahba Murugabaskar Balan Karine A. Cohen-Solal Interferon Lambda: A New Sword in Cancer Immunotherapy Clinical and Developmental Immunology |
| title | Interferon Lambda: A New Sword in Cancer Immunotherapy |
| title_full | Interferon Lambda: A New Sword in Cancer Immunotherapy |
| title_fullStr | Interferon Lambda: A New Sword in Cancer Immunotherapy |
| title_full_unstemmed | Interferon Lambda: A New Sword in Cancer Immunotherapy |
| title_short | Interferon Lambda: A New Sword in Cancer Immunotherapy |
| title_sort | interferon lambda a new sword in cancer immunotherapy |
| url | http://dx.doi.org/10.1155/2011/349575 |
| work_keys_str_mv | AT ahmedlasfar interferonlambdaanewswordincancerimmunotherapy AT walidabushahba interferonlambdaanewswordincancerimmunotherapy AT murugabaskarbalan interferonlambdaanewswordincancerimmunotherapy AT karineacohensolal interferonlambdaanewswordincancerimmunotherapy |